Cargando…
Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?
The global roll-out of Xpert MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA) has changed the diagnostic landscape of tuberculosis (TB). More than 16 million tests have been performed in 122 countries since 2011, and detection of multidrug-resistant TB has increased three- to eight-fold compared to conven...
Autores principales: | Albert, Heidi, Nathavitharana, Ruvandhi R., Isaacs, Chris, Pai, Madhukar, Denkinger, Claudia M., Boehme, Catharina C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967565/ https://www.ncbi.nlm.nih.gov/pubmed/27418550 http://dx.doi.org/10.1183/13993003.00543-2016 |
Ejemplares similares
-
Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis
por: Haraka, Frederick, et al.
Publicado: (2021) -
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
por: Steingart, Karen R, et al.
Publicado: (2014) -
Xpert® Mtb/Rif assay for pulmonary tuberculosis and rifampicin resistance in adults
por: Steingart, Karen R, et al.
Publicado: (2013) -
Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
por: Horne, David J, et al.
Publicado: (2019) -
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults
por: Kohli, Mikashmi, et al.
Publicado: (2021)